Eli Lilly weight loss drug cuts risk of developing diabetes in trial

Health

Eli Lilly Weight Loss Drug Cuts Risk Of Developing Diabetes In Trial

By CNBC

An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March 28, 2024. Eli Lilly's highly popular weight loss drug reduced the risk of developing Type 2 diabetes by 94% in obese or overweight adults w ...Read more

Related Posts

Amit Elor is a record-breaking Olympic wrestling gold medalist. She still felt ‘a little bit of imposter syndrome’ in Paris

Amit Elor is a record-breaking Olympic wrestling gold medalist. She still felt ‘a little bit of imposter syndrome’ in Paris

Aug 07, 2024
Stranded astronauts face increased cancer risk and vision loss

Stranded astronauts face increased cancer risk and vision loss

Aug 13, 2024
What to know about menopause, according to a doctor

What to know about menopause, according to a doctor

Aug 10, 2024
Lilly's weight loss drug cuts diabetes risk by 94% in three-year trial, company says

Lilly's weight loss drug cuts diabetes risk by 94% in three-year trial, company says

Aug 20, 2024
We use cookies to help provide you with the best experience when you visit our websites. By using this site you consent to the use of cookies on your device. see our cookie policy.